Clarification regarding recent decision from NICE

Oncopeptides has, as reported in the media, decided to not pursue an appraisal with the National Institute for Health And Care Excellence (NICE) in the United Kingdom at this time. This as the process of submitting an evidence submission requires both time and resources that is currently needed for other market access opportunities. The company still intends to seek access to the UK at a later point, as outlined in its previously communicated European launch plan.

On Thursday morning, the company clarified this in an interview with the news agency Direkt, which can be read here (Swedish only): https://www.placera.se/placera/telegram/2024/04/25/oncopeptides-nice-rekommenderar-ej-pepaxti-med-dexametason-ny.html

For further information, please contact David Augustsson, Head of Investor Relations and Communications: david.augustsson@oncopeptides.com; +46 076-2293868